※ 引述《Dimitre (迪米崔)》之銘言：
: 1.原文連結：
: ※過長無法點擊者必須縮網址
: https://reurl.cc/GVGreD
: 2.原文內容：
: Moderna’s closely watched early-stage human trial for a coronavirus vaccine
: produced Covid-19 antibodies in all 45 participants, the biotech company
: announced Monday.
: Each participant was assigned to receive a 25 microgram, 100 mcg or 250 mcg
: dose, with 15 people in each dose group. Study participants received two
: doses of the potential vaccine via intramuscular injection in the upper arm
: approximately 28 days apart. Data on a second dose was not available for the
: 250 mcg group, the company said.
: At day 43, or two weeks following the second dose, levels of binding
: antibodies in the 25 mcg group were at the levels generally seen in blood
: samples from people who recovered from the disease, the company said.
: Antibodies in the 100 mcg had antibodies that “significantly exceeded levels
: ” in recovered patients.
: The vaccine also produced neutralizing antibodies against Covid-19 in at
: least eight participants, the company said. Four participants were assigned
: to receive a 25 microgram dose, while the other four received 100 mcg. Levels
: of neutralizing antibodies were at or above levels in blood samples, the
: company said. Data on neutralizing antibodies for the other participants were
: not yet available, Moderna said.
: “These interim Phase 1 data, while early, demonstrate that vaccination with
: mRNA-1273 elicits an immune response of the magnitude caused by natural
: infection starting with a dose as low as 25 μg,” Tal Zaks, the chief
: medical officer at Moderna, said in s statement.
: “When combined with the success in preventing viral replication in the lungs
: of a pre-clinical challenge model at a dose that elicited similar levels of
: neutralizing antibodies, these data substantiate our belief that mRNA-1273
: has the potential to prevent COVID-19 disease and advance our ability to
: select a dose for pivotal trials,” Zaks added.
: There are formally approved treatments for Covid-19, which has killed at
: least 315,225 and sickened 4.7 million people worldwide since emerging from
: the Chinese city of Wuhan more than 4 months ago, according to data compiled
: by Johns Hopkins University.
: Moderna has been fast-tracking work with the National Institutes of Health,
: an agency within the Department of Health and Human Services, to develop a
: vaccine.
: The company said the vaccine was generally safe and well tolerated.
: The potential vaccine by Moderna contains genetic material called messenger
: RNA, or mRNA, that was produced in a lab. The mRNA is a genetic code that
: tells cells what to build — in this case, an antigen that may induce an
: immune response for the virus.
: The phase 1 trial took place at the Kaiser Permanente Washington Health
: Research Institute in Seattle, Washington. It tested the vaccine on 45 males
: and non-pregnant females between the ages of 18 and 55.
: 3.心得/評論：
: ※必需填寫滿20字
: 粗略翻譯
: Moderna公布早期臨床試驗報告
: 45個受試者分為25mg ,100mcg, 250mcg不等劑量疫苗的組別
: 每組各15個
: 所有受試者除了250mcg的以外都隔一個月施打兩劑
: 在研究的第43天 25mcg的受試者體內的抗體量跟得過COVID-19又痊癒的人一樣
: 100mcg的受試者體內抗體量遠多於痊癒的人
: 少數受試者甚至有能直接對抗COVID病毒的抗體
: Moderna目前盤前大漲25% 小道直接噴到600點
: 明天台股又要噴出了嗎
: 國光生 高端疫苗又怎麼走?
: -----補充一下-----
: 1.其他報導有指出"安全性,耐受性"都很好
: 2.打低劑量25mcg兩次就有不錯數量的抗體
: 3.FDA已經同意phase II trial 接下來七月準備phase III..這超速會不會年底前就上市?
雖然成果是正面的
但似乎也是意料之中
而且新聞也說最快2021年初才會投入市場
2021年耶
所以呢？雖然這隻股票可以投資啦
但今年還是要戴口罩不是嗎？
說口罩股立刻下去的沒邏輯吧
股價通常都反映未來1到2季
明年的事還很久吧
要不然你看國巨明明知道今年EPS至少25－30元
現在為什麼400元還站不穩?
但我可以告訴你現在投資國巨中長多很安全
問題是想投資國巨的不急啊
過2個月再買也可以
第四季之後的經濟狀況跟當下很難扯在一起
大立光也只是說四丶五月比較差
未來不確定，如果要是我說預期明年iphone大熱賣
我現在大立光就馬上飆上去嗎？
口罩丶額溫槍就是短多
額溫槍大家知道國外訂單能見度排到第三季
口罩開放外銷這個是當下可看到的
且表現出來的數字就是漂亮
這樣口罩丶額溫槍的股價要再維持高檔一個月沒問題的
雖然每天會震盪，但看起來短多是沒錯
心臟小的可以不碰防疫股
但空下去絕對不明智
總之，明天開紅盤，大家賺大錢
--
: 1.原文連結：
: ※過長無法點擊者必須縮網址
: https://reurl.cc/GVGreD
: 2.原文內容：
: Moderna’s closely watched early-stage human trial for a coronavirus vaccine
: produced Covid-19 antibodies in all 45 participants, the biotech company
: announced Monday.
: Each participant was assigned to receive a 25 microgram, 100 mcg or 250 mcg
: dose, with 15 people in each dose group. Study participants received two
: doses of the potential vaccine via intramuscular injection in the upper arm
: approximately 28 days apart. Data on a second dose was not available for the
: 250 mcg group, the company said.
: At day 43, or two weeks following the second dose, levels of binding
: antibodies in the 25 mcg group were at the levels generally seen in blood
: samples from people who recovered from the disease, the company said.
: Antibodies in the 100 mcg had antibodies that “significantly exceeded levels
: ” in recovered patients.
: The vaccine also produced neutralizing antibodies against Covid-19 in at
: least eight participants, the company said. Four participants were assigned
: to receive a 25 microgram dose, while the other four received 100 mcg. Levels
: of neutralizing antibodies were at or above levels in blood samples, the
: company said. Data on neutralizing antibodies for the other participants were
: not yet available, Moderna said.
: “These interim Phase 1 data, while early, demonstrate that vaccination with
: mRNA-1273 elicits an immune response of the magnitude caused by natural
: infection starting with a dose as low as 25 μg,” Tal Zaks, the chief
: medical officer at Moderna, said in s statement.
: “When combined with the success in preventing viral replication in the lungs
: of a pre-clinical challenge model at a dose that elicited similar levels of
: neutralizing antibodies, these data substantiate our belief that mRNA-1273
: has the potential to prevent COVID-19 disease and advance our ability to
: select a dose for pivotal trials,” Zaks added.
: There are formally approved treatments for Covid-19, which has killed at
: least 315,225 and sickened 4.7 million people worldwide since emerging from
: the Chinese city of Wuhan more than 4 months ago, according to data compiled
: by Johns Hopkins University.
: Moderna has been fast-tracking work with the National Institutes of Health,
: an agency within the Department of Health and Human Services, to develop a
: vaccine.
: The company said the vaccine was generally safe and well tolerated.
: The potential vaccine by Moderna contains genetic material called messenger
: RNA, or mRNA, that was produced in a lab. The mRNA is a genetic code that
: tells cells what to build — in this case, an antigen that may induce an
: immune response for the virus.
: The phase 1 trial took place at the Kaiser Permanente Washington Health
: Research Institute in Seattle, Washington. It tested the vaccine on 45 males
: and non-pregnant females between the ages of 18 and 55.
: 3.心得/評論：
: ※必需填寫滿20字
: 粗略翻譯
: Moderna公布早期臨床試驗報告
: 45個受試者分為25mg ,100mcg, 250mcg不等劑量疫苗的組別
: 每組各15個
: 所有受試者除了250mcg的以外都隔一個月施打兩劑
: 在研究的第43天 25mcg的受試者體內的抗體量跟得過COVID-19又痊癒的人一樣
: 100mcg的受試者體內抗體量遠多於痊癒的人
: 少數受試者甚至有能直接對抗COVID病毒的抗體
: Moderna目前盤前大漲25% 小道直接噴到600點
: 明天台股又要噴出了嗎
: 國光生 高端疫苗又怎麼走?
: -----補充一下-----
: 1.其他報導有指出"安全性,耐受性"都很好
: 2.打低劑量25mcg兩次就有不錯數量的抗體
: 3.FDA已經同意phase II trial 接下來七月準備phase III..這超速會不會年底前就上市?
雖然成果是正面的
但似乎也是意料之中
而且新聞也說最快2021年初才會投入市場
2021年耶
所以呢？雖然這隻股票可以投資啦
但今年還是要戴口罩不是嗎？
說口罩股立刻下去的沒邏輯吧
股價通常都反映未來1到2季
明年的事還很久吧
要不然你看國巨明明知道今年EPS至少25－30元
現在為什麼400元還站不穩?
但我可以告訴你現在投資國巨中長多很安全
問題是想投資國巨的不急啊
過2個月再買也可以
第四季之後的經濟狀況跟當下很難扯在一起
大立光也只是說四丶五月比較差
未來不確定，如果要是我說預期明年iphone大熱賣
我現在大立光就馬上飆上去嗎？
口罩丶額溫槍就是短多
額溫槍大家知道國外訂單能見度排到第三季
口罩開放外銷這個是當下可看到的
且表現出來的數字就是漂亮
這樣口罩丶額溫槍的股價要再維持高檔一個月沒問題的
雖然每天會震盪，但看起來短多是沒錯
心臟小的可以不碰防疫股
但空下去絕對不明智
總之，明天開紅盤，大家賺大錢
--
All Comments